The Maximally Effective Glaucoma Shunt
Glaucoma impacts 80 million patients globally. Glaucoma is a disease that damages the eye's optic nerve. It usually happens when aqueous humor builds up in the front of the eye (Anterior Chamber). This extra fluid increases the eye's intraocular pressure, damaging the optic nerve. Damage to the optic nerve caused by glaucoma leads to loss of visual field, usually starting from the periphery and eventually leading to the loss of central vision and blindness.
Current solutions, aimed at controlling the intraocular pressure by reducing the aqueous humor production or increasing its drainage/absorption include drops, laser surgery, MIGS (Minimally Invasive Glaucoma Shunts), incisional (angle) surgery and glaucoma drainage devices (shunt). None of there provide a long-term remedy.
The CorNeat eShunt is poised to revolutionize the treatment of glaucoma. It is designed to regulate the intraocular pressure and addresses the shortcomings of existing solutions. Using advanced materials, the eShunt inlet, which is placed in the anterior chamber angle, mimics the trabecular mesh function in terms of flow resistance. The eShunt outlet is uniquely positioned in the intraconal space, an area that does not scar and clog and can absorb the drained aqueous humor. The eShunt tube, which is covered by a synthetic ECM layer, seamlessly integrates with the ocular tissue as it traverses the subconjunctival space.
Inlet (regulating pressure)
Provides deterministic IOP - inlet mimics trabecular meshwork's adaptive pressure regulation as flow increases with pressure elevation.
Prolonged patency - outlet uniquely positioned deep in the orbit where there is only fat and no scar tissue.
Tube (ocular Integration)
Biologically integrates with neighboring tissue - porous, biocompatible, non-degradable polymers mimicking human Extra Cellular Matrix (ECM).
Does not rely on tissue or scarring process for flow control and won't clog as its outlet is placed intraconally.
Ease of Implantation
CorNeat eShunt's implantation procedure can be done in 10 to 15 minutes and does not require any introducer or specific tool.
CorNeat eShunt's tube is covered with a synthetic, non-degradable, ECM-like material that stimulates cellular growth - integrating the tube into the subconjunctival space. This eliminates the need for using a patch to minimize the risk of conjunctival.
CorNeat eShunt Advantages
The CorNeat eShunt has successfully passed initial bench test and animal trials demonstrating the ability to reduce and regulate intraocular pressure. The R&D and Pre-Clinical phases are expected to be completed within 12-15 months.
CorNeat eShunt device marketing is pending regulatory approvals.